1.2M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Arun Das | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| Michael Gerard | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Anup Marda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Gwendolyn K. Binder-Scholl | President, Science & Tech. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Steven Nichtberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Scott C. Brun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Catherine Bollard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Shawn Cline Tomasello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Richard C. Henriques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Anup Marda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Steven Nichtberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 353,000 | 353,000 | - | - | Stock Option (Right to Buy) | |
| Gwendolyn Binder-Scholl | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Michael Gerard | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Arun Das | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Binder-Scholl Gwendolyn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 19 Jan 2024 | 11,000 | 31,000 (0%) | 0% | 1.0 | 11,110 | Common Stock |
| Gwendolyn Binder-Scholl | See Remarks | Sale of securities on an exchange or to another person at price $ 20.33 per share. | 19 Jan 2024 | 700 | 20,000 (0%) | 0% | 20.3 | 14,229 | Common Stock |
| Binder-Scholl Gwendolyn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2024 | 11,000 | 100,756 | - | - | Stock Option (Right to Buy) | |
| Gwendolyn Binder-Scholl | See Remarks | Sale of securities on an exchange or to another person at price $ 19.54 per share. | 19 Jan 2024 | 10,300 | 20,700 (0%) | 0% | 19.5 | 201,211 | Common Stock |
| Binder-Scholl Gwendolyn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 11,000 | 111,756 | - | - | Stock Option (Right to Buy) | |
| Binder-Scholl Gwendolyn | See Remarks | Sale of securities on an exchange or to another person at price $ 22.22 per share. | 19 Dec 2023 | 3,132 | 20,000 (0%) | 0% | 22.2 | 69,593 | Common Stock |
| Binder-Scholl Gwendolyn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 19 Dec 2023 | 11,000 | 31,000 (0%) | 0% | 1.0 | 11,110 | Common Stock |
| Binder-Scholl Gwendolyn | See Remarks | Sale of securities on an exchange or to another person at price $ 21.76 per share. | 19 Dec 2023 | 7,868 | 23,132 (0%) | 0% | 21.8 | 171,196 | Common Stock |
| Gwendolyn Binder-Scholl | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 21 Aug 2023 | 11,000 | 31,000 (0%) | 0% | 1.0 | 11,110 | Common Stock |
| Gwendolyn Binder-Scholl | See Remarks | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 21 Aug 2023 | 10,700 | 20,300 (0%) | 0% | 13.4 | 143,436 | Common Stock |
| Gwendolyn Binder-Scholl | See Remarks | Sale of securities on an exchange or to another person at price $ 13.82 per share. | 21 Aug 2023 | 300 | 20,000 (0%) | 0% | 13.8 | 4,147 | Common Stock |
| Gwendolyn Binder-Scholl | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2023 | 11,000 | 155,756 | - | - | Stock Option (Right to Buy) | |
| Shawn Cline Tomasello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2023 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Gwendolyn Binder-Scholl | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 19 Jul 2023 | 11,000 | 31,000 (0%) | 0% | 1.0 | 11,110 | Common Stock |
| Gwendolyn Binder-Scholl | See Remarks | Sale of securities on an exchange or to another person at price $ 13.67 per share. | 19 Jul 2023 | 8,185 | 22,815 (0%) | 0% | 13.7 | 111,879 | Common Stock |
| Gwendolyn Binder-Scholl | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 11,000 | 166,756 | - | - | Stock Option (Right to Buy) | |
| Gwendolyn Binder-Scholl | See Remarks | Sale of securities on an exchange or to another person at price $ 14.26 per share. | 19 Jul 2023 | 2,815 | 20,000 (0%) | 0% | 14.3 | 40,143 | Common Stock |
| Gwendolyn Binder-Scholl | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 11,000 | 177,756 | - | - | Stock Option (Right to Buy) | |
| Gwendolyn Binder-Scholl | See Remarks | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 20 Jun 2023 | 11,000 | 20,000 (0%) | 0% | 13.0 | 142,925 | Common Stock |
| Gwendolyn Binder-Scholl | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 20 Jun 2023 | 11,000 | 31,000 (0%) | 0% | 1.0 | 11,110 | Common Stock |
| Scott C. Brun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Catherine Bollard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Richard C. Henriques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Gwendolyn Binder-Scholl | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 176,000 | 176,000 | - | - | Stock Option (Right to Buy) | |
| Steven Nichtberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 411,600 | 411,600 | - | - | Stock Option (Right to Buy) | |
| Anup Marda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Michael Gerard | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 112,500 | 112,500 | - | - | Stock Option (Right to Buy) | |
| Arun Das | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Steven Nichtberger | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.25 per share. | 19 Oct 2022 | 8,127 | 986,483 (4%) | 0% | 1.2 | 10,152 | Common Stock |
| Gwendolyn Binder-Scholl | See Remarks | Purchase of securities on an exchange or from another person at price $ 0.99 per share. | 18 Oct 2022 | 20,000 | 20,000 (0%) | 0% | 1.0 | 19,894 | Common Stock |
| Anup Marda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.99 per share. | 18 Oct 2022 | 50,000 | 50,000 (0%) | 0% | 1.0 | 49,620 | Common Stock |
| Catherine Bollard | Director | Purchase of securities on an exchange or from another person at price $ 0.99 per share. | 18 Oct 2022 | 1,000 | 1,000 (0%) | 0% | 1.0 | 994 | Common Stock |
| Steven Nichtberger | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.99 per share. | 18 Oct 2022 | 141,873 | 978,356 (4%) | 0% | 1.0 | 141,008 | Common Stock |
| Catherine Bollard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to buy) | |
| Scott C. Brun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Richard C. Henriques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to buy) | |
| Steven Nichtberger | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 31 Jan 2022 | 50,000 | 836,483 (3%) | 0% | 1.0 | 50,500 | Common Stock |
| Steven Nichtberger | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 50,000 | 229,677 | - | - | Stock Option (Right to Buy) | |
| Arun Das | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Michael Gerard | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Anup Marda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Gwendolyn Binder-Scholl | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Steven Nichtberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 380,000 | 380,000 | - | - | Stock Option (Right to Buy) | |
| Michael Gerard | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Scott C. Brun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Catherine Bollard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 22,000 | 22,000 | - | - | Stock Option (Right to buy) | |
| Brian Daniels | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 22,000 | 0 | - | - | Stock Option (Right to buy) | |
| Richard C. Henriques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 22,000 | 22,000 | - | - | Stock Option (Right to buy) | |
| Steven Nichtberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 333,500 | 333,500 | - | - | Stock Option (Right to Buy) | |
| Gwendolyn Binder-Scholl | EVP, Science & Technology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Anup Marda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 113,500 | 113,500 | - | - | Stock Option (Right to Buy) | |
| J. Brian Stalter | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 64,500 | 64,500 | - | - | Stock Option (Right to Buy) | |
| Steven Nichtberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2020 | 93,226 | 93,226 | - | - | Stock Option (Right to Buy) | |
| J. Brian Stalter | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2020 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 38,238 | 38,238 | - | - | Stock Option (Right to Buy) | |
| Anup Marda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 24,711 | 24,711 | - | - | Stock Option (Right to Buy) | |
| Steven Nichtberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Brian Daniels | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2020 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Steven Nichtberger | Director, President & CEO | 31 Dec 2019 | 93,225 | 93,225 | - | - | Stock Option (Right to Buy) | ||
| Steven Nichtberger | Director, President & CEO | 29 Oct 2019 | 90,725 | 0 | - | - | Series A-1 Preferred Stock | ||
| Steven Nichtberger | Director, President & CEO | 29 Oct 2019 | 60,483 | 786,483 (3%) | 0% | - | Common Stock | ||
| David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2019 | 48,836 | 48,836 | - | - | Stock Option (Right to Buy) | |
| Anup Marda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2019 | 66,463 | 66,463 | - | - | Stock Option (Right to Buy) | |
| Gwendolyn Binder-Scholl | EVP, Science & Technology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2019 | 29,908 | 29,908 | - | - | Stock Option (Right to Buy) | |
| Steven Nichtberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2019 | 99,714 | 99,714 | - | - | Stock Option (Right to Buy) |